Blog

Careers

Advertise

Contact

logo
  • About
    • Mission
    • What Is A GPO ?
    • Policy Positions
    • HSCA Committees
    • Member Organizations
    • FAQ
    • Leadership
    • HSCA Staff
    • Contact
  • Events
    • National Pharmacy Forum 2022
    • Past Events
  • CHeS
    • CHeS Total Visibility Project
    • CHeS Membership
    • CHeS Resources
  • Issues
  • Resources
    • Studies
    • Hospital Testimonials
    • Supplier Endorsements
    • Small Supplier Portal
    • Congressional Resources
    • COVID-19 Recommendations
    • COVID-19 Response Efforts
  • News
  • About
    • Mission
    • What Is A GPO ?
    • Policy Positions
    • HSCA Committees
    • Member Organizations
    • FAQ
    • Leadership
    • HSCA Staff
    • Contact
  • Events
    • National Pharmacy Forum 2022
    • Past Events
  • CHeS
    • CHeS Total Visibility Project
    • CHeS Membership
    • CHeS Resources
  • Issues
  • Resources
    • Studies
    • Hospital Testimonials
    • Supplier Endorsements
    • Small Supplier Portal
    • Congressional Resources
    • COVID-19 Recommendations
    • COVID-19 Response Efforts
  • News

Comments of the Healthcare Supply Chain Association (HSCA) to FDA on Facilitating Competition and Innovation in the Biological Products Marketplace

September 21, 2018 by admin 2018 Press Releases 0 comments

On behalf of the Healthcare Supply Chain Association (HSCA), thank you for the opportunity to provide comments on the U.S. Food and Drug Administration’s (FDA) “Facilitating Competition and Innovation in the Biological Products Marketplace.”

The ability to safely substitute FDA-approved biosimilars for reference biologics will be critical to realizing the full cost-savings potential of biosimilars and will ensure that patients have timely access to safe, less-costly therapies. HSCA and its member healthcare group purchasing organizations are committed to lowering costs through increased competition and innovation in the healthcare marketplace and have consistently advocated for policies to ensure a pathway to market for biosimilars that prioritizes patient safety and cost savings.

We applaud the FDA for recognizing the value of a competitive and innovative biosimilars marketplace and respectfully offer the following recommendations to promote the swift uptake of biosimilar products:

Read the full comments…

Prev
Next

Related Posts

HSCA Joins Leading Healthcare Organizations in Supporting the CREATES Act (S.974)
June 7, 2018

We, the undersigned, commend you for your leadership and commitment to reducing...

Learn more
HSCA Comments on DEA Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances
September 19, 2018

On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the...

Learn more
HSCA Announces Healthcare Cybersecurity Key Considerations
April 17, 2018

The Healthcare Supply Chain Association (HSCA) today announced the release of key...

Learn more
HSCA Releases Second Annual Report on Value GPOs Deliver to the Healthcare Supply Chain
August 21, 2018

Washington, DC (August 21, 2018) – The Healthcare Supply Chain Association...

Learn more

Our Office

Healthcare Supply Chain Association
1341 G Street NW Suite 600
Washington, DC 20005

Phone: 202.629.5833
Fax: 202.466.9666
Email: info@supplychainassociation.org

LATEST NEWS

  • HSCA Support Letter to the House Committee on Energy & Commerce on House Passage of FDA User Fee Reauthorizations
    June 30, 2022
  • ANALYSIS: GPOs Helped Increase Domestic Manufacturing Capacity, Protected Hospitals and Patients from Thousands of Fraudulent Sellers, and Helped Identify and Bring New Suppliers to Market to Avert Supply and Drug Shortages During COVID-19
    April 20, 2022